We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Digital Pathology Market to Grow Exponentially in China

By LabMedica International staff writers
Posted on 05 May 2014
An extensive Frost & Sullivan (San Antonio, TX, USA) analysis identifies factors that propel exponential growth of the medical digital pathology market in China.

The new Frost & Sullivan analysis – Analysis of the Digital Pathology Market in China – finds that the market earned revenues of USD 259 million in 2013 and estimates this to rocket up to USD 1,914.8 million in 2019. More...
A burgeoning elderly population cohort the number of people over 60 years is projected to increase 8 million annually and reach 243 million by 2020 has heightened the need for pathological diagnosis. The situation is further aggravated by a rising incidence of cancer.

The advent of digital pathology is expected to help revolutionize healthcare in China and overcome challenges in clinical practices, research, and medical education. Favorable government healthcare reforms, such as initiatives on nationwide telepathology consultation and quality control programs, as well as the growing need for integration of healthcare delivery, will usher in a wave of digital pathology adoption. “Leveraging advancements in information technology and big data analytics will shift future healthcare deliveries towards personalized, evidence-based treatments,” said Raymond Chong, Frost & Sullivan Healthcare Research Analyst; “Healthcare will revolve around collaboration among medical institutions with emphasis on predictive and preventive medicine, widening the potential of the Chinese digital pathology market.”

Unfortunately, high investment and maintenance costs, low sample volume, and limited returns are hurdles to the use of digital pathology, particularly in rural regions. With barely 20% of medical resources allocated to rural areas, healthcare institutions remain reluctant to purchase these solutions. Vendors should identify and understand targeted end-user segments and deliver cost-effective, customized solutions to sustain business viability. Implementing unique pricing strategies in which products and services are priced in line with customer budgets and expectations will enable manufacturers to retain market share.

“Digital pathology system vendors should seek partnerships with various participants along the value chain, including software vendors and device manufacturers,” advised Chong; “Aligning investment plans with government and stakeholders’ agenda to build long-term partnerships will further bolster their position.”

Related Links:

Frost & Sullivan
Frost & Sullivan Connected Health Growth Partnership Service



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.